P59.09 Landscape of Targetable Genomic Alterations in Hispanic/Latinx Patients With Non-Small Cell Lung Cancers

Abstract

Despite significant advances in lung cancer therapeutics, real-world data describing the genomic landscape of non-small cell lung cancer among diverse populations remains limited. We aim to describe the landscape of targetable genomic alterations in Hispanic/Latinx patients with non-small cell lung cancers in an international database. Patient-specific targetable genomic alterations were analyzed using the open-source international genomic data-sharing consortium American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange (GENIE). Using cBioPortal as a query database, we analyzed 656 samples from 595 Hispanic/Latinx patients with lung adenocarcinoma for the prevalence of targetable genomic alterations among this ethnic group, divided by sex and age group: =<45 years-old, 46-65 years-old, or >65 years-old. Among 656 samples from 595 unique Hispanic/Latinx patients with lung adenocarcinoma, 59.5% (n=354) of samples were from females, and 40.5% (n=241) from males. The most common targetable genomic alterations were mutations in the EGFR gene in 27.9% (n=183) of samples, KRAS in 20.1% (n=132), ERBB2 in 6.4% (n=42), and BRAF in 5.8% (n=38). Fusions involving ALK (3.5%, n=23), ROS1 (2.6%, n=13), and RET (1.5%, n=10) involved a minority of samples. Among age groups, females represented a statistically significantly larger prevalence of the samples in younger adults, with 63% among those =<45 years old, 67% 46-65 years old, and 58% on those >65 years old. The prevalence of genomic alterations by age group and sex are presented in Table 1.Table 1Genomic AlterationsFemales % (n)Males % (n)p-value=<45 years-old % (n)46-65 years-old % (n)>65 years-old % (n)p-valueEGFR mutations32.0 (127)21.6 (56)<0.00126.7 (16)26.4 (79)29.9 (88)0.617KRAS mutations20.9 (83)18.9 (49)0.30211.7 (7)20.7 (62)21.1 (62)0.233BRAF mutations4.0 (16)8.5 (22)0.0141.7 (1)5.4 (16)7.1 (21)0.229ERBB2 mutations6.8 (27)5.8 (15)0.3693.3 (2)7.7 (23)5.9 (17)0.389ALK fusions5.1 (20)1.2 (3)0.00516.7 (10)3.0 (9)1.4 (4)<0.001ROS1 fusions3.1 (10)1.7 (3)0.2779.1 (4)3.8 (9)0<0.001RET fusions1.5 (6)1.5 (4)0.6063.3 (2)1.3 (4)1.4 (4)0.491 Open table in a new tab Among an international sample of Hispanic/Latinx with lung adenocarcinoma women and younger adults with lung cancer displayed a larger prevalence of targetable genomic alterations. As therapeutics advances continue to develop in lung cancer care, understanding the genomic landscape of diverse populations with lung cancer will help ensure equitable delivery across diverse racial/ethnic groups.